RUNX1T1 and neoplasm: By binding to the promoter of CDKN1A, RUNX1T1 inhibits histone acetylation, which leads to E2F upregulation and carcinogenesis acceleration, an expected modulation accompanying the loss of tumor-repressor RB1 in SCLC [14].